BACKGROUND: Current treatments for @entity170 are associated with various side effects and do not prevent the age-related decrease in osteoblast number. The objective of this study was to evaluate the effects of iQPR-H   O on osteogenesis. METHODS: @entity19 fibroblast NIH3T3 and pre-osteoblastic @entity19 cells were cultured in medium prepared with iQPR-H   O or unprocessed mineral water (control cells), and proliferation and differentiation were assessed by @entity98 and alkaline phosphatase assay, respectively. Mineral deposition by the cells was determined using @entity6033 staining. A @entity19 model of @entity170 , ovariectomized SAMP8 @entity19 , was used to evaluate the effects of iQPR-H   O on osteogenesis in vivo. @entity19 were given either iQPR-H   O or unprocessed mineral water (control group) for four months after which bone mass density (BMD) measurements were made using a bone densitometer and @entity1710 and @entity1711 staining of bone samples. RESULTS: NIH3T3 cells grown in medium prepared with iQPR-H   O exhibited significantly greater proliferation. NIH3T3 and @entity19 cells demonstrated a significant increase in alkaline phosphatase levels in the iQPR-H   O group. @entity19 cells showed mineralization at day 28. mRNA expression levels of both osteopontin and @entity2447 in @entity19 cells were higher in the iQPR-H   O group compared with the control group. After four months, significantly greater bone regeneration was evident in ovariectomized SAMP8 @entity19 administered iQPR-H   O as compared with control group. CONCLUSIONS: iQPR-H   O may reduce the symptoms of @entity170 by improving osteogenesis.

Use of iQPR-H   O for bone regeneration and its potential in the improvement of XXXX .

@entity2447 :: ('12393(Tax:10090)', 'Gene') :: ['runt-related transcription factor 2'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mouse', 'MC3T3-E1', 'mouse', 'Mice'] @entity1711 :: ('MESH:D004801', 'Chemical') :: ['eosin'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity6033 :: ('MESH:C004468', 'Chemical') :: ['Alizarin red S'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']
@entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']
